Search Results for "rapid"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for rapid. Results 101 to 110 of 543 total matches.

Treatment of Hypothermia

   
The Medical Letter on Drugs and Therapeutics • Dec 23, 1994  (Issue 938)
° to 106° F (32.2° to 41.1° C) raises core temperature rapidly and can be used to treat short-term ...
This winter physicians in many area may see patients suffering from hypothermia. Old age, lack of adequate housing, drug overdose and alcohol ingestion are often prediposing factors, but hypothermia also occurs in healthy young people after prolonged exposure to cold due to incapacitating trauma or cold water immersion. Hypothermia associated with exhaustionduring outdoor sports activities can occur even at relatively mild temperatures.
Med Lett Drugs Ther. 1994 Dec 23;36(938):116-7 |  Show IntroductionHide Introduction

Trovafloxacin

   
The Medical Letter on Drugs and Therapeutics • Mar 13, 1998  (Issue 1022)
, with or without food, is rapidly absorbed from the gastrointestinal tract, reaching peak levels in serum in one ...
Trovafloxacin (Trovan - Pfizer) and its prodrug alatrofoxacin (Trovan IV) are new fluroroquinolones marketed for an unusually wide variety of infections, including oral and intravenous treatment of nosocomial and community-acquired pneumonia, acute ecerbations of chronic bronchitis, acute sinusitis, complicate intra-abdominal and pelvic infections, diabetic foot infection, uncomplicated urinary tract infection, prostatitis, cervicitis and uncomplicated gonorrhea.
Med Lett Drugs Ther. 1998 Mar 13;40(1022):30-1 |  Show IntroductionHide Introduction

Argatroban For Treatment of Heparin-Induced Thrombocytopenia

   
The Medical Letter on Drugs and Therapeutics • Feb 05, 2001  (Issue 1097)
activate platelets and damage vascular endothelium, resulting in rapid platelet destruction ...
Argatroban, a small-molecule synthetic derivative of L-arginine, is a direct thrombin inhibitor approved by the FDA for use as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT).
Med Lett Drugs Ther. 2001 Feb 5;43(1097):11-2 |  Show IntroductionHide Introduction

Spritam - A New Formulation of Levetiracetam for Epilepsy

   
The Medical Letter on Drugs and Therapeutics • Jun 20, 2016  (Issue 1497)
for Epilepsy The FDA has approved a rapidly disintegrating tablet formulation of the antiepileptic drug ...
The FDA has approved a rapidly disintegrating tablet formulation of the antiepileptic drug levetiracetam (Spritam – Aprecia) for adjunctive treatment of partialonset, myoclonic, and primary generalized tonicclonic seizures. Oral and intravenous formulations of levetiracetam (Keppra, and generics) have been available for years. Although approved by the FDA only as adjunctive therapy, levetiracetam is commonly used as monotherapy for partial-onset and generalized seizures and may also be effective in treating absence seizures and seizures of Lennox-Gastaut syndrome.
Med Lett Drugs Ther. 2016 Jun 20;58(1497):78-9 |  Show IntroductionHide Introduction

An Oral Cholera Vaccine for Travelers (Vaxchora)

   
The Medical Letter on Drugs and Therapeutics • Aug 29, 2016  (Issue 1502)
or (less commonly) O139 causes diarrhea that can be severe and can rapidly Table 1. Recommendations ...
The FDA has approved Vaxchora (PaxVax), a single-dose, oral, live-attenuated cholera vaccine, to protect against disease caused by Vibrio cholerae serogroup O1 in adults 18-64 years old traveling to cholera-affected areas. Vaxchora is the only cholera vaccine available in the US. A whole-cell killed injectable vaccine was previously approved, but is no longer available in the US.
Med Lett Drugs Ther. 2016 Aug 29;58(1502):113-4 |  Show IntroductionHide Introduction

Fosfomycin for Urinary Tract Infections

   
The Medical Letter on Drugs and Therapeutics • Jul 18, 1997  (Issue 1005)
to fosfomycin emerges rapidly, but cross-resistance with other antimicrobials has been uncommon (DS Reeves, J ...
Fosfomycin, a broad-spectrum antibiotic used parenterally in Europe for many years, has been approved by the US Food and Drug Administration (FDA) as fosfomycin tromethamine (Monurol - Forest) for single-dose oral treatment of uncomplicated urinary tract infections in women.
Med Lett Drugs Ther. 1997 Jul 18;39(1005):66-8 |  Show IntroductionHide Introduction

Continuous Glucose Monitoring

   
The Medical Letter on Drugs and Therapeutics • May 02, 2011  (Issue 1363)
also include alarms for hypoglycemia, hyperglycemia, or a rapid rise or fall in blood sugar. All CGM ...
A variety of continuous glucose monitoring (CGM) devices have been used in an effort to reduce the hypoglycemia and wide glucose excursions that complicate insulin treatment of diabetes. Since the last Medical Letter issue reviewing such devices, some new devices and some new data on old devices have become available. The devices currently marketed in the US for personal use are listed in Table 1.
Med Lett Drugs Ther. 2011 May 2;53(1363):35-6 |  Show IntroductionHide Introduction

Certolizumab Pegol (Cimzia) and Ustekinumab (Stelara) for Psoriatic Arthritis

   
The Medical Letter on Drugs and Therapeutics • Feb 03, 2014  (Issue 1435)
tolerate a TNF inhibitor.6 CLINICAL STUDIES — A randomized, double-blind, 24-week trial (RAPID-PsA ...
Certolizumab pegol (Cimzia – UCB), a tumor necrosis factor (TNF) inhibitor previously approved for treatment of Crohn's disease and rheumatoid arthritis, and ustekinumab (Stelara – Janssen), a human interleukin-12 and -23 antagonist previously approved for treatment of moderate-to-severe plaque psoriasis, have now been approved by the FDA for treatment of active psoriatic arthritis.
Med Lett Drugs Ther. 2014 Feb 3;56(1435):10-2 |  Show IntroductionHide Introduction

Brexanolone (Zulresso) for Postpartum Depression

   
The Medical Letter on Drugs and Therapeutics • May 06, 2019  (Issue 1571)
on their efficacy are limited. Electroconvulsive therapy is rapid-acting and has been reported to be effective ...
The FDA has approved the GABAA receptor modulator brexanolone (Zulresso – Sage Therapeutics) for IV treatment of postpartum depression (PPD). Brexanolone is the first drug to be approved by the FDA for this indication.
Med Lett Drugs Ther. 2019 May 6;61(1571):68-70 |  Show IntroductionHide Introduction

In Brief: Budeprion XL 300 Has Been Withdrawn

   
The Medical Letter on Drugs and Therapeutics • Oct 29, 2012  (Issue 1402)
XL 300 mg releases bupropion more rapidly than Wellbutrin XL 300 mg, the original brand name product ...
The FDA has asked Impax Laboratories/Teva Pharmaceuticals to stop production and distribution of Budeprion XL 300 mg, a generic extended-release formulation of the antidepressant bupropion (Wellbutrin XL), because it has found that Budeprion XL 300 mg releases bupropion more rapidly than Wellbutrin XL 300 mg, the original brand name product. Patients switched from the brand name to the generic formulation have complained for years that the generic was less effective and caused more side effects than the original formulation. In 2007, ConsumerLab.com, an independent laboratory, conducted...
Med Lett Drugs Ther. 2012 Oct 29;54(1402):88 |  Show IntroductionHide Introduction